GeNeuro SA
Trending Articles
Related Content
Ingredients
GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis
ANGEL-MS extension study will offer the 260 patients enrolled in the on-going Phase IIb CHANGE-MS study the opportunity to continue their treatment for an additional two years and will provide additional efficacy and tolerance data